key: cord-1018485-4rn8or3a
authors: Koh, Pei Xuan; Tay, Kay Yaw; Yeo, Tianrong; Singh, Dinesh Rambachan; Koh, Jasmine Shimin; Thirugnanam, Umapathi N; Saini, Monica
title: Glial fibrillary acidic protein astrocytopathy in a patient with recent mRNA SARS-CoV-2 vaccination COVERSHEET
date: 2021-12-22
journal: Neuroimmunology Reports
DOI: 10.1016/j.nerep.2021.100053
sha: fed30aa10cfdbfdfbe5bbc30de8258a99b56a8f2
doc_id: 1018485
cord_uid: 4rn8or3a

Background Literature describing triggers of GFAP astrocytopathy (GFAP-A) is limited. We report a case of GFAP-A in a patient with recent messenger ribonucleic acid (mRNA) severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) vaccination and discuss the possible pathogenesis. Case description A 45-year-old gentleman presented with features of meningoencephalitis 31 days after the first dose and 4 days after the second dose of mRNA SARS-CoV-2 vaccination. He sequentially developed brainstem/cerebellar, autonomic and cord dysfunction. Cerebrospinal fluid was positive for GFAP autoantibody. Clinical improvement occurred after intravenous methylprednisolone and immunoglobulins. Conclusion Although we are uncertain of a causal link of GFAP-A to mRNA vaccine, indirect activation of an underlying dysregulated immune milieu is plausible.

Glial fibrillary acidic protein astrocytopathy (GFAP-A) is a rare neurological condition, first described in 2016. It has a varied clinical presentation that includes meningoencephalitis, myelitis, ataxia, and autonomic dysfunction, and has been described to occur in association with other autoimmune diseases, or follow viral infections. [1] [2] [3] While viral infections are recognized as triggers of immune-mediated neurological conditions, the association between vaccination and such conditions is inconsistent. 4, 5 The possibility of novel messenger ribonucleic acid (mRNA) severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) vaccines aberrantly activating the immune system, and triggering an autoimmune condition, has been previously suggested. 6, 7 We describe a patient with GFAP-A, and a preceding history of Moderna SARS-CoV-2 (mRNA-1273) vaccination. Our report contributes to the knowledge of this rare entity, and surfaces the possibility of it being triggered by an mRNA vaccine.

We describe clinical details and investigations of a patient diagnosed with GFAP-A, in close temporal association with SARS-CoV-2 mRNA vaccination.

A 45-year-old Chinese gentleman, with a past medical history of type 2 diabetes mellitus and hypertension, presented with fever, cough and nausea of 3 days' duration, followed by altered mental status. He had received his first and second dose of Moderna SARS-CoV-2 (mRNA-1273) vaccine 31 and 4 days prior respectively. At presentation, he was febrile, confused (Glasgow Coma Scale 11), and had right focal motor seizures. Physical examination revealed nuchal rigidity, without lateralizing focal neurological deficits. Cerebrospinal fluid (CSF) showed a lymphocytic pleocytosis and raised protein [ Table 1 ]. Empirical treatment for meningoencephalitis (intravenous ceftriaxone, vancomycin, acyclovir, oral doxycycline) was instituted, along with levetiracetam for acute symptomatic seizures. Investigations are summarized in Table 1 . No infective agent was identified in CSF, serum, and respiratory swabs performed in the first week of illness.

In his second week of illness, he sequentially developed signs of brainstem and cerebellar dysfunction (persistent hiccups, titubation, tremors, ocular flutter), along with dysautonomia.

Fundoscopic examination did not reveal any optic disc swelling. Magnetic resonance imaging (MRI) of the brain [ Figure 1A ] showed subtle leptomeningeal signal abnormality around the medulla, and serum autoimmune encephalitis panel was negative. Between day 15 -18, he developed progressive lower limb weakness and numbness. Physical examination revealed asymmetric lower limb weakness (upper motor neuron pattern), distal areflexia, and thoracic sensory level. Repeat CSF analysis (2-3 weeks) showed persistent lymphocytic pleocytosis [ Table 1 ]. MRI spine showed long segment leptomeningeal enhancement of the brainstem and spinal cord, most prominently involving the cervical segment [ Figure 1B , C].

The constellation of symptoms and signs, together with the lack of an infective aetiology led to the clinical impression of an immune-mediated meningoencephalomyelitis. CSF GFAP antibody (Ab) was tested, which returned positive (Mayo clinic laboratory: indirect immunofluorescence assay titre 1:16; cell binding assay positive). A screen for underlying oncologic diseases was negative [ Table 1 ]. Subsequent to clinical diagnosis, methylprednisolone (intravenous, 1g/day) was given for 5 days, whereupon rapid resolution of fever, confusion and brainstem/cerebellar signs was noted. A tailing dose of oral prednisolone (initial dose of 1mg/kg/day) was continued. Lower limb weakness reached a nadir (power-medical research council grade 1-2) between the third and fourth week of his illness. Intravenous immunoglobulin (2 g/kg body weight, over 5 days) was initiated. Further gradual improvement was noted in lower limb function. Clinical course was complicated by femoral vein thrombosis, secondary to a venous line, and cholecystitis. At the time of this report, he remains paraparetic (power-medical research council grade 3-5) and requires an indwelling urinary catheter.

GFAP is an intracellular filament protein expressed predominantly in astrocytes, but not limited to the central nervous system (CNS). 8 As GFAP is not accessible to circulating immunoglobulin G (IgG), GFAP-specific cytotoxic T cells are believed to be the key players in pathogenesis of GFAP-A. Pathological evidence from these patients shows perivascular lymphocytic infiltrate composed predominantly of CD8+ T lymphocytes. 9 In addition, other immune system components, including microglia, macrophages, and cytokines, may play a role in disease pathogenesis.

Reported associations for GFAP-A include viral infections, neoplasia, and dysregulation of T-cell function. [1] [2] [3] To date, there are no published reports of GFAP-A associated with vaccination. Vaccines may trigger autoimmune conditions via bystander activation of dormant autoreactive T-cells, epitope spread, molecular/epitope mimicry, or may intensify pre-existing immune dysregulation via pro-inflammatory responses. 7 Reports of myelitis and encephalitis following adenoviral vector ChAdOx1 SARS-CoV-2 vaccine have emerged recently. 10, 11 The novel nature of mRNA vaccines has raised concerns over immune-mediated adverse events (AE). The mechanism of action of mRNA vaccines involves introducing the gene of the spike protein inside the host cell, and translation of mRNA within the cytoplasm. 12 Though SARS-CoV-2 mRNA vaccines utilize modified mRNA (encoding stabilised prefusion S-protein) that may not trigger pathogen-associated molecular pattern sensing mechanisms, 13 potent adaptive B-and T-cell mediated immune response is documented following mRNA vaccination; thus bystander activation of autoreactive T-cells may occur. 13 Cross-reactivity of spike protein antibody with human tissue proteins (including myelin basic protein and S100B), has been demonstrated, surfacing the possibility of mimotope-related immune injury. 14 The latency period between mRNA vaccine administration and immune system activation is unclear but may be extrapolated from existing data. Rare cases of myocarditis (latency ≥ 24 hours), and a patient with multisystem inflammatory syndrome (latency 2 days) have been reported following mRNA SARS-CoV-2 vaccines. 15, 16 Recent reports of neurological AE in relation to mRNA vaccines include encephalopathy/encephalitis following the first dose (latency 7-21 days), though lack of CSF abnormalities in one reported patient limits interpretation. [17] [18] Reports of encephalitis in publicly available databases recording vaccine related AE, are rare. 19 Lack of clinical and investigative details significantly limit interpretation in terms of causality.

In a recent case series of neurological autoimmune diseases following vaccinations against SARS-CoV-2, 8 cases were noted following the first mRNA vaccine dose, whereas 5 cases occurred after the second dose. 20 Studies on vaccine efficacy have shown that after the first dose of mRNA vaccine, the levels of neutralising antibodies are only <5% of the post-second dose peak . 21 It is postulated that the first dose of mRNA vaccination primes memory B and T cell and the second dose boosts the immune response. Therefore, mechanisms of protection may differ after two doses versus one dose, where neutralising antibodies mediate the predominant protective mechanism following subsequent doses of vaccine, whereas protection after one dose may be a result of non-neutralising antibodies leading to other effector mechanisms and/or is medicated by a relatively low frequency of antigen-specific T cells. 21 The World Health Organization (WHO) tool for causality assessment of adverse effects following immunization is hinged upon the presence of "known causal association with vaccine or vaccination". 23 This limits assessment for rare conditions such as GFAP-A. Pooled data for immune-mediated conditions occurring in close temporal relation to mRNA vaccines, exclusion of alternative aetiologies, and demonstration of a higher incidence following vaccination is essential for determining causality. Similar neurological autoimmune conditions have also been described following adenoviral vectored 20 and inactivated 24 SARS-CoV-2 vaccines and while we are unable to establish causality in our patient, the temporal association and biological plausibility of a vaccine-triggered autoimmunity are notable.

However, we must emphasise that the safety profile of mRNA vaccines is extremely reassuring, and cases such as our patient would be exceedingly rare.

In conclusion, we describe a case of GFAP-A following mRNA SARS-CoV-2 vaccination, and propose vaccination as a possible trigger. In light of the ongoing COVID-19 pandemic, the rarity of this association needs to be emphasised, and the underlying mechanism of vaccine-triggered autoimmunity remains a hypothesis.

Conception 

Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy. A Novel Meningoencephalomyelitis

Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients

Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year

Neurologic Disease after Yellow Fever Vaccination

Vaccines and the risk of acute disseminated encephalomyelitis

The SARS-CoV-2 as an instrumental trigger of autoimmunity

Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon

GFAP and desmin expression in lymphatic tissues leads to difficulties in distinguishing between glial and stromal cells. Sci Rep

CD8+ T-cell predominance in autoimmune glial fibrillary acidic protein astrocytopathy

Acute myelitis and ChAdOx1 nCoV-19 vaccine: Casual or causal association

Postvaccinal encephalitis after ChAdOx1 nCov-19

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations

SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines (Basel)

Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases

The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism

Multisystem inflammatory syndrome in adult following the SARS-CoV-2 vaccine

Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine

Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination

Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use

Acute disseminated encephalomyelitislike presentation after an inactivated coronavirus vaccine

DNA-deoxyribonucleic acid; ds-double stranded; GAD-glutamic acid decarboxylase HbA1c-glycosylated haemoglobin; HIV-human immunodeficiency virus

MRI-Magnetic resonance imaging; ng-Nano gram; PCR-Polymerase Chain Reaction

Syncytial Virus; u-micro

U-units; umol-micromoles

WBC-white blood cells